Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Prescott Group Capital Management Provides Update on Its Discussions with PharmAthene

Phil Frohlich‘s Prescott Group Capital Management, has provided, in a newly amended filing with the Securities and Exchange Commission, an update on its negotiations with the board of PharmAthene, Inc. (NYSEMKT:PIP) regarding a shareholders meeting proposal launched by Prescott regarding the company’s merger with Theraclone Sciences.


According to the filing, the board declined both proposals for a meeting, stating that the fund should have submitted a statement with the SEC regarding the meeting 30 days before the planned date. In this way, the meeting can only be conducted after the December 3, the date at which the shareholders of PharmAthene will vote in favor or against the merger. At the same time, Prescott stated that the board mentioned that it does not desire to engage in discussions proposed by the fund. Taking into account the board’s position, the meeting will have no effect regarding the merger. According to the previous letter, Prescott requested a meeting to be held on November 29.

Prescott disclosed holding a 10% stake in the company over a month ago. PharmAthene and Theraclone announced about entering into a merger agreement under an all-stock deal at the beginning of August. As stated earlier, the shareholders of the company will vote the matter at the beginning of December. Under the terms of the agreement, Theraclone shareholders will receive shares issued by Pharmathene in such a way that their proportion will amount to 50% of the stock of the new company.

In the latest round of 13F filings, Jim Simons‘ Renaissance Technologies disclosed initiating a small position in the company, which contains 146,000 shares, worth $307,000. At the same time, Ken Griffin‘s Citadel Investment Group closed its option positions, and Sophrosyne Capital, led by Benjamin J Taylor sold of its long stake in the company, which earlier contained around 804,900 shares.

Disclosure: none

Recommended Reading:

Mario Gabelli, GAMCO Disclose Activist Moves into Superior Industries International & Griffin Land & Nurseries

Billionaire Carl Icahn Sells His Entire Stake in Take-Two Interactive Software Back to the Company

Steven Cohen, SAC Capital Disclose New 5% Stake in Tile Shop Holdings

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!